Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00148837 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis

Study acronym: PRAZOR
StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Active, Not Recruiting to Completed Primary and study completion dates: Dec 2008 · Interventions: Peg-interferon alpha 2b (drug) (Drug), Prazosin (drug) (Drug), Ribavirin (drug) (Drug) to Peg-interferon alpha 2b + Ribavirin(drug) (Drug), Prazosin (drug) (Drug) · Secondary endpoints: details revised at 3 of 3 entries · 2 morev6 Show all 6 changesShow less
    • Primary and study completion dates: Dec 2008
    • Interventions: Peg-interferon alpha 2b (drug) (Drug), Prazosin (drug) (Drug), Ribavirin (drug) (Drug) to Peg-interferon alpha 2b + Ribavirin(drug) (Drug), Prazosin (drug) (Drug)
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study arms: 0 to 2
    • Collaborators expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv5
  3. Trial status: Recruiting to Active, Not Recruiting Site details revisedv4 Show all 2 changesShow less
    • Site details revised
  4. Re-verified, no change to tracked fieldsv3
  5. Study Identification, Study Statusv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Viral hepatitis C prognosis is related to the presence of a fibrosis and to the risk of developing cirrhosis or hepatic cancer. The study will evaluate the efficacy of prazosin to make hepatic fibrosis regress, in patients with chronic hepatitis C and severe fibrosis.
Trial Details
NCT Number NCT00148837
Lead Sponsor French National Agency for Research on AIDS and Viral Hepatitis
Collaborators: Pfizer
Conditions Hepatitis C, Chronic, Fibrosis
Enrollment 112 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov